<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268472</url>
  </required_header>
  <id_info>
    <org_study_id>GP30101-P4-11</org_study_id>
    <nct_id>NCT04268472</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg (&quot;Jonson&amp;Jonson&quot;, Russia)</brief_title>
  <official_title>Crossover, Open-label, Randomized, Single-dose, Bioequivalence Study of GP30101 Film-coated Tablets (LLC &quot;GEROPHARM&quot;, Russia) 800 mg Versus Prezista® (Jonson&amp;Jonson, Russia) Film-coated Tablets 800 mg in Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg (&quot;Jonson&amp;Jonson&quot;,
      Russia)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the pharmacokinetic parameters, relative bioavailability and bioequivalence
      of drugs containing darunavir - GP30101 and Prezista® in healthy volunteers after single
      orally administered dose, under fed conditions A comparative analysis of adverse events
      aditionally conducted in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Actual">September 6, 2019</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>C(max)</measure>
    <time_frame>-35 min prior dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetics by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>-35 min prior dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetics by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T(max)</measure>
    <time_frame>-35 min prior dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetics by Assessment of Time of Maximum concentration observed (T(max)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T(1/2)</measure>
    <time_frame>-35 min prior dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetics by Assessment of elimination half-life T(1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K(e)</measure>
    <time_frame>-35 min prior dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetics by Assessment of elimination rate constant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>TR Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In first Intervention period subjects was administered test medecine (GP30101) and in seconde Intervention period subjects was administered reference medecine (Prezista)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In first Intervention period subjects was administered reference medecine (Prezista) and in seconde Intervention period subjects was administered test medecine (GP30101)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP30101</intervention_name>
    <description>Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer</description>
    <arm_group_label>TR Sequence</arm_group_label>
    <other_name>First aIntervention Period</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prezista®</intervention_name>
    <description>Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer</description>
    <arm_group_label>RT Sequence</arm_group_label>
    <other_name>First aIntervention Period</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP30101</intervention_name>
    <description>Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer</description>
    <arm_group_label>RT Sequence</arm_group_label>
    <other_name>Second Intervention Period</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prezista®</intervention_name>
    <description>Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer</description>
    <arm_group_label>TR Sequence</arm_group_label>
    <other_name>Second Intervention Period</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Male aged 18 to 45 years.

          -  Verified diagnosis is &quot;healthy&quot; according to data Standard clinical, laboratory and
             Instrumental methods of examination.

          -  Body mass index between 18,5 and 30 kg/m2, with body weight 60-100 kg

          -  Consent to comply with an adequate method of effective contraception throughout the
             study.

          -  The consent of volunteers to all restrictions imposed during the study.

          -  Russian Federation Citizens

        Exclusion Criteria:

          -  History of allergic problems/events.

          -  Hypersensitivity to heparin, darunavir or any of the excipients of the drugs studied.

          -  Any acute and chronic diseases, including but not limited to cardiovascular system
             diseases, bronchopulmonary diseases, neuroendocrine systems diseases, as well as
             diseases of the gastrointestinal tract, liver, kidneys, blood.

          -  Positive testing for hepatitis C (antibodies) or hepatitis B (surface antigen), HIV
             (antibodies to HIV-1/2), syphilis (antibodies to Treponema pallidum).

          -  The WHO norms deviations of the heart rate (60-89), Sistolic BP (100-130 mm Hg),
             Diatolic BP (60-89 mm Hg), respiratory rate (12-20), body temperature (35.7 - 37.6
             °C).

          -  Abnormal ECG during screening.

          -  Inaccessible veins of the upper extremities, vein thrombosis, thrombophlebitis in the
             anamnesis or in the family history of the next of kin, &quot;compromised&quot; veins due to
             frequent previous venipuncture.

          -  Psychiatric disorders, history of epilepsy and seizures.

          -  Surgical interventions on the gastrointestinal tract (except appendectomy).

          -  Acute infectious diseases in less than 4 weeks before the start of the study.

          -  Regular medication use (intake) less than 2 weeks before the start of the study.

          -  Significant loss of blood within 3 months prior to screening, including but not
             limited to blood donation or extended surgery or trauma resulting in the blood loss.

          -  History of alcohol or drugs abuse or any indication of the regular use of more than 10
             units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of
             alcohol 40%).

          -  Positive test results for alcohol or drug use.

          -  Nicotine addiction, regular use of tobacco, including all types of electronic
             cigarettes, less than 6 months prior to screening.

          -  Participation in a clinical trial of any drugs (including experimental) or
             experimental medical devices for 3 months or 5 half-lives, whichever is longer, before
             the study.

          -  Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before
             the start of the study.

          -  Any diet (for example, vegetarian, fasting, etc.) or lifestyle (including night work
             and extreme physical activity) that may interfere with the study.

          -  Taking medications that have a pronounced effect on hemodynamics, liver function, etc.
             (barbiturates, omeprazole, cimetidine, etc.) less than 30 days before the start of the
             study.

          -  Volunteers who are obvious or likely, according to the investigator, are unable to
             understand and evaluate the information on this study as part of the process of
             signing informed consent, in particular regarding the expected risks and possible
             discomfort.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yarosslavl Clinical Hospital #3</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

